> > Loizzo (Lega): "Long-acting biologics are a breakthrough for severe asthma and nasal polyposis."

Loizzo (Lega): "Long-acting biologics are a breakthrough for severe asthma and nasal polyposis."

Loizzo (Lega): "Long-acting biologics are a breakthrough for severe asthma and nasal polyposis."

(Adnkronos) - "Long-acting biologics represent a true revolution in the treatment of severe asthma and nasal polyps because they promote better adherence to therapy and make patients less dependent on continuous administration," said Simona Loizzo, c...

(Adnkronos) – "Long-acting biologics represent a true revolution in the treatment of severe asthma and nasal polyposis because they promote better adherence to therapy and make patients less dependent on continuous administration." This was stated by Simona Loizzo, member of the XII Social Affairs Committee of the Chamber of Deputies, speaking today in Rome at the institutional conference "Therapeutic Innovation for Longevity and Healthy Aging," organized by the Longevitas Foundation with the unconditional contribution of GSK. 

 “Uncontrolled asthma makes social, work, and emotional life difficult.

Long-acting biologics are also innovative because, in addition to increasing patient compliance, as confirmed by the literature, they significantly improve clinical outcomes and lead to a better quality of life,” he underlined.  

According to Loizzo, therapeutic innovation represents a fundamental lever for meeting the needs of chronically ill patients and promoting more effective management of highly complex respiratory diseases.

"For the future, I hope for ever greater pharmacological innovation, because these innovative drugs are truly revolutionary. Investing in innovation and research means improving the quality of life of our patients," he concluded. 

News

webinfo@adnkronos.com (Web Info)

Continue on the app The news of your city, in real time.
Open in app App Store